Bio-Thera is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $18.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Bio-Thera's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Starjemza |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved 22 May 2025; launched 6 Nov 2025; interchangeable | $6.1B |
| Simponi Immgolis |
Johnson & Johnson | Biosimilar | 2026 | FDA-approved 15 May 2026; launch expected in Q4 2026; interchangeable | $2.7B |
| Cosentyx BAT2306 |
Novartis | Biosimilar | 2029 | In clinical trials. Phase 3 complete | $6.7B |
| Nucala BAT2606 |
GSK | Biosimilar | 2029 | In clinical trials | ≈$2.6B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Bio-Thera's share of it.
Bio-Thera sells US copies of one of these drugs: Stelara (since 6 Nov 2025). It also has FDA approval for Simponi, with no US launch confirmed; and copies in development for Cosentyx and Nucala. Of the 70 makers we follow, 21 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.